Journal
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
Volume 39, Issue 6, Pages 712-728Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0317167100015547
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research [13129]
- Heart and Stroke Foundation Canada
- Alzheimer's Association, US
- Alzheimer Society of Canada
- National Institute of Health
- Canadian Stroke Network
- Alzheimer Society of Saskatchewan
- Alzheimer's Association
- Canadian Institutes of Health Research
- Scottish Rite Charitable Foundation of Canada
Ask authors/readers for more resources
Alzheimer's disease (AD), considered the commonest neurodegenerative cause of dementia, is associated with hallmark pathologies including extracellular amyloid-beta protein (A beta) deposition in extracellular senile plaques and vessels, and intraneuronal tau deposition as neurofibrillary tangles. Although AD is usually categorized as neurodegeneration distinct from cerebrovascular disease (CVD), studies have shown strong links between AD and CVD. There is evidence that vascular risk factors and CVD may accelerate A beta 40-42 production/ aggregation/deposition and contribute to the pathology and symptomatology of AD. A beta deposited along vessels also causes cerebral amyloid angiopathy. Amyloid imaging allows in vivo detection of AD pathology, opening the way for prevention and early treatment, if disease-modifying therapies in the pipeline show safety and efficacy. In this review, we review the role of vascular factors and A beta, underlining that vascular risk factor management may be important for AD prevention and treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available